Enforcement record
先駆け審査指定制度対象品目の募集 disclosure naming ステラファーマ株式会社
This page records one action from a Japanese government disclosure, including the published name, governing law, authority, action details, and official source.
Action type
先駆け審査指定制度対象品目の募集
Law
Pharmaceutical Affairs Act
Authority
Ministry of Health, Labour and Welfare
Action date
5 October 2017
Current page: Enforcement record
This screen focuses on one disclosed action: the published name, governing law, authority, facts, source status, and review evidence.
Source verification
Public-source and preservation status
- Publishing authority
- Ministry of Health, Labour and Welfare
- Official source URL
- Recorded by RegBase
- Entity match
- Not confirmed; shown under the published name
- Kiroku preservation
- Queued for preservation
- Captured: Jul 12, 2026, 03:35 PM JST
“Confirmed” means that RegBase matched this record to the cited public disclosure or entity under the stated checks. It does not verify the truth of the disclosure or guarantee the entity’s current status, creditworthiness, or any legal conclusion.
Available sources and saved files are listed in the public documents section below.
Public documents and saved materials
View the original publications, see what was preserved, or download each file below.
Loading materials…
Action summary
- Company
- ステラファーマ株式会社Japanese onlyOriginal: ステラファーマ株式会社
- Governing law
- Pharmaceutical Affairs Act薬事法
- Action type
- 先駆け審査指定制度対象品目の募集先駆け審査指定制度対象品目の募集
- Action date
- 5 October 2017
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
SPM-011 Recurrent malignant glioma, inoperable local recurrence of head and neck cancer, and locally advanced head and neck cancer (non-squamous cell carcinoma)
Show original Japanese text
SPM-011 ※再発悪性神経膠腫・切除不能な局所再発頭頸部癌並びに局所進行頭頸部癌（非扁平上皮癌）
Compliance context
Context neededThis is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.
Japanese regulatory disclosure under Pharmaceutical Affairs Act.
Review the original Japanese source and determine relevance to your counterparty-risk workflow.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.